Not in Madrid: The 2020 virtual congress of the European Society for Medical Oncology (#ESMO20) is underway and in this post we’re taking a look at some of the highlights from Friday at ESMO20, a day when we’ve seen a raft of posters and mini-orals released for on-demand viewing.
With COVID-19 rates rising across Europe, ESMO are to be congratulated for pivoting to a virtual meeting that allows the sharing of knowledge and advancement of the field. It was definitely the right decision in light of the ongoing travel challenges, quarantines, not to mention restrictions on large groups in many countries.
For our daily ESMO20 coverage – just as we would if we had been in Madrid – we’ve been listening to some of the on-demand mini-oral presentations and associated discussions, with a view to picking out and commenting on a few that stood out for us.
As always we’re approaching this from a cancer new product development perspective, and our choice is always a balance of emerging new targets and drugs, as well as following those we’ve previously written about.
To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
A new dawn or a rapid sunset for epigenetics in oncology R&D?
Epigenetic therapies have had somewhat of a chequered history in oncology R&D, but new targets are always cropping up to tempt us to look further.
One emerging target we’ve come across – this is only the fourth mention here since January 2019 – is starting to gather steam with new players entering the landscape, as well as emerging preclinical and clinical evidence suggesting it might be well worth a serious look.
Here we look at the potential role this epigenetic target may have to play in a variety of difficult to treat cancers, as well as how it could enhance existing therapies in new combination approaches.
Could we combine these inhibitors with chemotherapy, with immunotherapy or DNA repair approaches? How does the therapeutic window stack up?
We look at the latest evidence from several sources and discuss where the opportunities might lie…
To learn more from our oncology analysis and get a heads up on insights and commentary an emerging area of epigenetics, subscribers can log-in or you can click to gain access to BSB Premium Content.
The Francis Crick Institute in London has an admirable program of engagement with the public and external researchers.
Attending a Crick Lecture recently presented by Cancer Research UK (CRUK) Chief Scientific Officer, Prof Karen Vousden CBE FRS, reminded me of my days as a PhD student at nearby King’s College London.
Regular BSB readers will recall that Prof Charles Swanton FRS is the Chief Clinician of CRUK.
In her Crick lecture, Prof Vousden elegantly explained to the audience why p53 mattered and how it might be targeted by small molecules.
What is the potential of this research for translational drug development? In this post, we take a look at new developments in the basic understanding of what p53 does, the current state of targeting p53 and Prof Vousden’s latest approaches.
To learn more from our latest biotech and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.